190A — Chordia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- ¥30bn
- ¥27bn
- ¥3bn
Annual income statement for Chordia Therapeutics, fiscal year end - August 31st, JPY millions except per share, conversion factor applied.
2022 August 31st | 2023 August 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | JAS | JAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0 | 2,500 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 1,844 | 2,288 |
| Operating Profit | -1,844 | 212 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -1,777 | 226 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -1,779 | 223 |
| Net Income Before Extraordinary Items | ||
| Net Income | -1,779 | 223 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -1,779 | 223 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -27.1 | 3.41 |
| Dividends per Share |